Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia
Conditions
Interventions
AXS-14 (Esreboxetine)
Placebo
Locations
16
United States
Clinical Research Site
Little Rock, Arkansas, United States
Clinical Research Site
Santa Ana, California, United States
Clinical Research Site
Cromwell, Connecticut, United States
Clinical Research Site
Jacksonville, Florida, United States
Clinical Research Site
Orlando, Florida, United States
Clinical Research Site
Tampa, Florida, United States
Start Date
January 14, 2026
Primary Completion Date
March 1, 2028
Completion Date
March 1, 2028
Last Updated
February 9, 2026
NCT07358754
NCT05901259
NCT03759522
NCT07230171
NCT07186751
NCT07023523
Lead Sponsor
Axsome Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions